FNCH
NASDAQFinch Therapeutics Group Inc.
Latest news
25 items- SECSEC Form 15-12G filed by Finch Therapeutics Group Inc.15-12G - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- SECSEC Form EFFECT filed by Finch Therapeutics Group Inc.EFFECT - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- SECSEC Form S-8 POS filed by Finch Therapeutics Group Inc.S-8 POS - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- SECSEC Form POS AM filed by Finch Therapeutics Group Inc.POS AM - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- SECSEC Form S-8 POS filed by Finch Therapeutics Group Inc.S-8 POS - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- SECSEC Form S-8 POS filed by Finch Therapeutics Group Inc.S-8 POS - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- SECSEC Form 25 filed by Finch Therapeutics Group Inc.25 - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- SECSEC Form 8-K filed by Finch Therapeutics Group Inc.8-K - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- PRFinch Announces Delisting from Nasdaq and SEC DeregistrationBOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (NASDAQ:FNCH) ("Finch" or the "Company"), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Global Select Market. Finch expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of its Common Stock on or about October 31, 2024. The removal of the Common Stock from Nas
- SECSEC Form 10-Q filed by Finch Therapeutics Group Inc.10-Q - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- SECSEC Form 8-K filed by Finch Therapeutics Group Inc.8-K - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- INSIDERDirector Smisek Jeffery A gifted 767 shares, decreasing direct ownership by 2% to 17,870 units (SEC Form 4)4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
- INSIDERSmisek Jeffery A gifted 3,750 shares (SEC Form 4)4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
- SECSEC Form 8-K filed by Finch Therapeutics Group Inc.8-K - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- SECSEC Form 8-K filed by Finch Therapeutics Group Inc.8-K - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- SECSEC Form 10-Q filed by Finch Therapeutics Group Inc.10-Q - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- NEWSFinch Therapeutics Has Been Granted European Patent Number EP3664823 Titled "Composition For Use In Preventing Or Treating An Enterococcal Blood Stream Infection".https://register.epo.org/application?number=EP18843863
- SECSEC Form 10-K/A filed by Finch Therapeutics Group Inc. (Amendment)10-K/A - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- NEWSWhy Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionShares of Teledyne Technologies Incorporated (NYSE:TDY) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter financial results and cut FY24 adjusted EPS guidance. Teledyne Technologies posted adjusted earnings of $4.55 per share, missing market estimates of $4.63 per share. The company's quarterly sales came in at $1.35 billion versus expectations of $1.40 billion, according to data from Benzinga Pro. Teledyne Technologies shares dipped 9.3% to $369.16 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE) gained 136% to $0.3570. BranchOu
- NEWSWhy Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionShares of The Travelers Companies, Inc. (NYSE:TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. Core income per share reached $4.69 from $4.11 a year ago, missing the $4.90 consensus forecast. Net income per share rose to $4.80 from $4.13 a year earlier. Travelers shares dipped 8.1% to $205.03 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers INVO Bioscience, Inc. (NASDAQ:INVO) shares shot up 256% to $2.78 after the company reported a year-over-year increase in fourth-quarter revenue results and said it remains on track to reach its goa
- NEWS12 Health Care Stocks Moving In Wednesday's Intraday SessionGainers INVO Bioscience (NASDAQ:INVO) stock rose 275.0% to $2.85 during Wednesday's regular session. The market value of their outstanding shares is at $7.4 million. As per the news, the Q4 earnings report came out yesterday. Vanda Pharma (NASDAQ:VNDA) stock moved upwards by 33.33% to $5.4. The company's market cap stands at $310.7 million. Galera Therapeutics (NASDAQ:GRTX) shares rose 27.76% to $0.22. The company's market cap stands at $11.8 million. SINTX Techs (NASDAQ:SINT) shares increased by 27.51% to $0.03. The company's market cap stands at $3.5 million. Viracta Therapeutics (NASDAQ:VIRX) stock moved upwards by 27.51% to $0.91. The company's market cap stands at $35.7 million. R
- NEWS12 Health Care Stocks Moving In Friday's After-Market SessionGainers Qilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. The company's market cap stands at $40.7 million. Allarity Therapeutics (NASDAQ:ALLR) stock rose 18.09% to $2.48. The market value of their outstanding shares is at $1.1 million. Galecto (NASDAQ:GLTO) stock increased by 5.58% to $0.72. The company's market cap stands at $19.4 million. Finch Therapeutics Gr (NASDAQ:FNCH) shares increased by 5.28% to $2.19. The company's market cap stands at $3.5 million. CNS Pharma (NASDAQ:CNSP) stock rose 4.97% to $0.26. The market value of their outstanding shares is at $2.7 million. Cormedix (NASDAQ:CRMD) shares rose 4.96% to $6.13. Th
- SECSEC Form 8-K filed by Finch Therapeutics Group Inc.8-K - Finch Therapeutics Group, Inc. (0001733257) (Filer)
- INSIDERSmisek Jeffery A sold $21,246 worth of shares (8,242 units at $2.58), closing all direct ownership in the company (SEC Form 4)4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
- SECSEC Form 144 filed by Finch Therapeutics Group Inc.144 - Finch Therapeutics Group, Inc. (0001733257) (Subject)
FNCH FAQ
7 questionsWhat does Finch Therapeutics Group Inc. do?
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and...Where does FNCH stock trade?
Finch Therapeutics Group Inc. (FNCH) is listed on NASDAQ.What sector and industry is FNCH in?
Finch Therapeutics Group Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Finch Therapeutics Group Inc. go public?
Finch Therapeutics Group Inc. (FNCH) completed its IPO in 2021.What are analysts saying about FNCH?
Finch Therapeutics Group Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $1700.00 price target on 2022-08-09. Recent price targets cluster around $1700.00.What companies are similar to FNCH?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare FNCH side-by-side with any of them on Quantisnow.How can I track FNCH on Quantisnow?
Quantisnow aggregates Finch Therapeutics Group Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FNCH to receive live email and push alerts on every new disclosure.